Non-Small Cell Lung Cancer

Developing New Therapies for Non-Small Cell Lung Cancer

Over the last 10 years the Non-Small Cell Lung Cancer (NSCLC) market has moved from platinum-based chemotherapy to personalized medicine. Types and sizes of target populations for development have reduced dramatically—costs and risk have not.

The sheer pace of development in NSCLC all but guarantees that diagnostic and treatment dynamics will change materially as new drugs are being developed. Adapting to these shifting sands of clinical practice can be daunting—and frustrating for even experienced and well capitalized companies.

At Syneos Health, we lead with a product development mindset, strategically integrating clinical development, medical affairs and commercial capabilities to address modern market realities in complex categories like NSCLC. Our experience includes:

Global experience in oncology and hematology trials since 2016; 549 studies involving 74,000+ patients.
Over 19,000 oncology & hematology sites activated in the last five years in our global network.

Our teams have deep experience that spans discovery to end of lifecycle. At each trial milestone, we have consultants who assess the landscape with a focus on early-stage commercialization strategy development, including indication prioritization, product/portfolio strategy, commercial model design, pricing and reimbursement, distribution strategy and global entry.